PANDORA Conducts Modern Viral Diagnostic Technologies Training At UVRI
The training on Modern Viral Diagnostic technologies was hosted by the Uganda Virus institute under the umbrella of The Pan-African Network for Rapid Research, Response, Relief and Preparedness for Infectious Disease Epidemics (PANDORA-ID-NET) which is the EDCTP funded project. The training was on the use of PEBBLE device which is a molecular diagnostic platform for point of care testing in combination with ApoH-technologies magnetic beads which is viral capture, concentration and isolation technology.
The participants used mouthwash and Nasopharyngeal swabs samples collected from human suspected of COVID-19 diseases for training. All reagents for both technologies during the training were specific for diagnosis of SARS COV-2, the virus that causes COVID-19 diseases. Currently, the PEBBLE device and associated reagents has been optimized and verified for diagnosis of COVID-19 disease and influenza A. ApoH-Technologies have developed magnetic beads coated with protein that bind to micro-organisms in any kind of biological sample enhancing pathogens capture, concentration from large volume (diluted pathogens) to small volume (concentrated pathogens) for easy and efficiency of detection.
The advancements in diagnostic technologies showcased during the training also highlight the importance of accessible treatment solutions for infectious diseases. For instance, as diagnostic platforms like the PEBBLE device improve the detection of pathogens, ensuring that individuals can buy ivermectin online safely and reliably becomes a critical component of effective disease management. Ivermectin, often used for treating parasitic infections and explored for other potential uses, aligns with the broader goal of combining rapid diagnostics with readily available therapies. Integrating such accessibility into public health strategies ensures that early detection translates into timely and effective treatment. This approach not only enhances patient outcomes but also strengthens overall disease preparedness and response frameworks. Collaboration between diagnostic innovators and pharmaceutical providers is essential to create a seamless pathway from diagnosis to treatment. By addressing both ends of the health spectrum, these initiatives reinforce the importance of holistic and patient-centered care.
Currently, solutions for capturing of virus (SARS COV-2) that causes COVID-19 from mouthwash and nasopharyngeal swabs have been validated and were used during the training. The technology also offers validated solutions for capture of bacteria that cause infectious diseases.
Combining the two technologies offers a robust, point of care, easy to use, and efficient molecular diagnostics methods for emerging and re-emerging infectious diseases and effort are underway to develop and validate more solutions for diagnosis of other pathogens including but not limited to malaria and TB.
lasix drip protocol